Gmax Biopharm
Manufacturing · 11-50 Employees
View Company Info for Free
Overview
Website
www.gmaxbiopharm.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Gmax Biopharm
About Gmax Biopharm LLC.: Gmax is a clinical stage biopharmaceutical company established in 2010 and headquartered in Hangzhou, China. It's a global company focusing on R&D, production and commercialization of antibody drugs targeting GPCRs. Gmax mainly works on cardiovascular, metabolic and cancer areas. Currently there are five drug development programs in different stages of clinical trials: GMA102 (type 2 diabetes), GMA105 (obesity), GMA301A (PAH for adult), GMA301B (PAH for children), GMA106 (obesity/T2DM/NASH). GMA131, an ETA specific ERA mAb for DKD/CKD, is about to enter into phase 1/2 trial in China and USA. Gmax's unique M-body technology empowers acting on two or more different targets to improve drug efficacy or broaden indications.Explore more
Popular SearchesGmax Biopharm LLCGmax Biopharm International LtdGmax BiopharmGmaxbiopharm鸿运华宁(杭州)生物医药有限公司SIC Code 28,283NAICS Code 32,325Show moreGmax Biopharm Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Gmax Biopharm your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Gmax Biopharm recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Gmax Biopharm
Check if Gmax Biopharm has recently received funding, and reach out quickly before it becomes old news!
Gmax Biopharm, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Gmax Biopharm is spiking on competitors!
Product Launch: Get notified when Gmax Biopharm launches new products
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Gmax Biopharm has new funding data
Click to see if Gmax Biopharm had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Gmax Biopharm
Find 3 more new buyers
Company Profile Activity
Activity Insights
Gmax Biopharm is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Gmax Biopharm is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Gmax Biopharm.
Gmax Biopharm Tech Stack
Gmax Biopharm News & Media
Gmax's GMA106, second generation obesity/T2DM/NASH mAb gives first in human dose
HANGZHOU, China, Nov. 11, 2021 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA106 was given to human subjects in a phase 1 study to investigate the safety, pharmacokinetics, and pharmacodynamics of this drug in the treatment of obesity. The study is a single dose,...GMAX Zhengzhou Manufacturing Site Breaks Ground
HANGZHOU, China, Dec. 15, 2020 /PRNewswire/ -- Gmax Biopharm today holds ground-breaking ceremony for its Zhengzhou, China manufacturing site which is the production base for its GMA102 (T2D), GMA105 (obesity), and GMA301A/B (PAH for adult and children) drugs to be launched between...GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial
HANGZHOU, China, Oct. 26, 2020 /PRNewswire/ -- Gmax Biopharm today announces that the first dose of GMA301 was given to the patient in its phase 1B trial to investigate the drug efficacy to treat pulmonary arterial hypertension (PAH). GMA 301 is the first antibody drug for PAH treatment....
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Gmax Biopharm
Sign Up For FreeTo access detailed company insights
About Gmax Biopharm LLC.: Gmax is a clinical stage biopharmaceutical company established in 2010 and headquartered in Hangzhou, China. It's a global company focusing on R&D, production and commercialization of antibody drugs targeting GPCRs. Gmax mainly works on cardiovascular, metabolic and cancer areas. Currently there are five drug development p... Read More
